AN2 Therapeutics Phase 3 Trial Pause Impacts Stock

AN2 Therapeutics Downgraded to “Perform” by Oppenheimer Following Pause in Phase 3 Trial

AN2 Therapeutics’ stock rating took a hit on Monday as Oppenheimer downgraded the company from an “Outperform” to a “Perform” rating. The decision followed an announcement from AN2 Therapeutics that it had paused enrollment for its pivotal Phase 3 trial of epetraborole. The treatment, which aims to address treatment-refractory Mycobacterium avium complex (MAC), showed potentially lower efficacy than expected.